A latest research reported that additional application of durvalumab and tremelimumab after chemoradiotherapy significantly improved survival in patients with locally advanced ESCC, especially in those with PD-L1 positive tumors (52). Here, CD274 is linked to esophageal squamous cell carcinoma.